Table 2.

Some examples of innovative pre-clinical nanomedicines system for chronic inflammatory diseases

Nanoparticles (Nps)	Main Compound	Inflammatory lesions	References
N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer NPs	Dexamethasone	Arthritis	Jia et al. (2020)
Nanoemulsion formulation of cationic lipid DOTAP	TNF-α siRNA	Parkinson’s disease	Yadav et al. (2019)
Omega-3 fatty acid-rich flaxseed oil-based nanoemulsion system	Cyclosporin A	neuroinflammation
Pegylated liposomes	Prednisolone	Renal ischemia and reperfusion injury	Van Alem et al. (2018)
Hyaluronic acid/chitosan NPs	Cytokine response modifier A pDNA	Osteoarthritis	Zhou et al. (2018a, b)
Hyaluronic acid-coated solid–lipid NPs	Prednisolone	Arthritis
Spherical polymeric Nano constructs	Dexamethasone		Lee et al. (2020)
Solid–lipid NPs	Dexamethasone and Butyrate		Dianzani et al. (2017)